| Sex | n (%) |
| Male | 14 (64) |
| Female | 8 (36) |
| Race/ethnicity | |
| White/non-Hispanic or unknown | 13 (59) |
| White/Hispanic | 7 (32) |
| Asian/non-Hispanic | 2 (9) |
| Median age, y (range) | 12 (1.3-22.3) |
| Lineage | |
| B-precursor ALL | 20 (91) |
| T-cell ALL | 2 (9) |
| Treatment attempts | |
| Failed 2 regimes | 17 (77) |
| Failed 3 regimes | 5 (23) |
| Previous BMT | |
| None | 18 (82) |
| Yes | 4 (18) |
| BM (at study entry) M3 | 22 (100) |
| Treatment data | |
| Bortezomib: 4 planned doses | 22 (100) |
| Completed therapy | 19 (86) |
| Induction death | 3 (14) |
| BM aplasia | None |
| Days to ANC > 750/μL, median (range) | 38 (27-48) |
| Days to platelets > 75 000/μL, median (range) | 35 (27-41) |
| Sex | n (%) |
| Male | 14 (64) |
| Female | 8 (36) |
| Race/ethnicity | |
| White/non-Hispanic or unknown | 13 (59) |
| White/Hispanic | 7 (32) |
| Asian/non-Hispanic | 2 (9) |
| Median age, y (range) | 12 (1.3-22.3) |
| Lineage | |
| B-precursor ALL | 20 (91) |
| T-cell ALL | 2 (9) |
| Treatment attempts | |
| Failed 2 regimes | 17 (77) |
| Failed 3 regimes | 5 (23) |
| Previous BMT | |
| None | 18 (82) |
| Yes | 4 (18) |
| BM (at study entry) M3 | 22 (100) |
| Treatment data | |
| Bortezomib: 4 planned doses | 22 (100) |
| Completed therapy | 19 (86) |
| Induction death | 3 (14) |
| BM aplasia | None |
| Days to ANC > 750/μL, median (range) | 38 (27-48) |
| Days to platelets > 75 000/μL, median (range) | 35 (27-41) |
ALL indicates acute lymphoblastic leukemia; ANC, absolute neutrophil count; BMT, BM transplantation; and M3, > 25% BM blasts.